Antimicrobial Prochelators Targeting Drug-Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rise of antibiotic resistance among bacteria, particularly against β-lactam antibiotics, limits treatment options as bacteria develop enzymes like β-lactamases that inactivate these drugs, and existing strategies for new antibiotics have been slow to develop effective solutions.
Innovation Solution
Development of antibacterial prodrugs that are activated by β-lactamase enzymes to release toxic metal chelating agents, targeting metal-dependent processes in resistant bacteria, thereby exacerbating bacterial killing while minimizing toxicity to mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibiotics are used to treat bacterial infections, then initial treatment effectiveness is achieved, but bacterial resistance develops rendering the drugs ineffective
Solution Approach 1:
The antibiotic is divided into two functional segments: a β-lactam core that targets bacterial cell wall synthesis and a metal-chelating moiety that sequesters essential metals. This segmentation allows the molecule to simultaneously attack bacteria through multiple mechanisms, delaying resistance development while maintaining initial effectiveness.
Solution Approach 2:
The patent creates a composite antibiotic molecule combining organic β-lactam structure with metal-chelating groups (such as hydroxyquinoline or pyrithione). This composite structure enables dual functionality: traditional cell wall inhibition plus metal deprivation, thereby extending the duration of antibiotic activity against resistant strains.
2Reliability
If metal chelators are applied systemically to kill bacteria, then antimicrobial activity increases, but toxicity to mammalian cells also increases
Solution Approach 1:
The metal-chelating property is localized to the antibiotic molecule rather than being systemically distributed. The chelator is covalently attached to the β-lactam core, ensuring that metal sequestration occurs only at the infection site where the antibiotic accumulates, thereby maintaining high antimicrobial activity while minimizing systemic cytotoxicity.
Solution Approach 2:
The β-lactam core acts as an intermediary vehicle that delivers the metal-chelating agent specifically to bacterial cells. The antibiotic component ensures targeted delivery to infected tissues, while the chelator component executes the metal-deprivation mechanism, separating the delivery function from the toxic action.
3Adaptability or versatility
If new antibiotic classes are developed to overcome resistance, then treatment options are expanded, but development time and resources increase
Solution Approach 1:
The patent creates a universal antibiotic platform based on the β-lactam core that can be adapted to target multiple resistance mechanisms. By modifying the metal-chelating groups attached to the core, different variants can address various resistant strains, providing versatile treatment options while building on existing β-lactam development knowledge and reducing overall development time.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The prodrug approach effectively targets resistant bacteria by releasing metal chelators in the presence of β-lactamases, enhancing antimicrobial activity and longevity, with reduced cytotoxicity to human cells, thus offering a promising solution to the growing antibiotic resistance crisis.
Implementation Method 1
β-lactamase enzymes that selectively convert a non-toxic, non-metal binding prochelator into a toxic metal chelating agent
Implementation Method 2
toxic metal chelating agent that harnesses the metallobiology along the host-pathogen interface to exacerbate bacterial killing
Data Source
AI summary
The present disclosure provides antibacterial prodrugs and methods of making and using the same.